Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 1.00 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.60 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.55 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.55 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.55 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.55 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6314091 | 0.99 | SIGMAR1 (0.97) | SIGMAR1NPY5RSSTR5GRIN2DGRIN3B | |
| SCHEMBL11838834 | 0.92 | SIGMAR1 (0.85) | SIGMAR1NPY5RGRIN2DGRIN3BGRIN1 | |
| SCHEMBL11834157 | 0.86 | SIGMAR1 (0.76) | SIGMAR1NPY5RGRIN2DGRIN3BGRIN1 | |
| SCHEMBL4214518 | 0.85 | SIGMAR1 (0.74) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4216497 | 0.85 | SIGMAR1 (0.74) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL749498 | 0.84 | SIGMAR1 (0.73) | SIGMAR1 | |
| SCHEMBL2359969 | 0.84 | SIGMAR1 (0.73) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2361177 | 0.84 | SIGMAR1 (0.73) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL12488997 | 0.84 | SIGMAR1 (0.73) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4068737 | 0.84 | SIGMAR1 (0.73) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10071095-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders | Janssen Pharmaceuticals, Inc. (US) | 2018-09-11 | — | — | US | disclosed |
| US-9828385-B2 | Spiro-oxazolones | HOFFMANN-LA ROCHE INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9737533-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals. Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170008901-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20160355522-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160067245-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| US-9226930-B2 | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals, Inc. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150141403-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2015-05-21 | — | — | US | disclosed |
| US-8937060-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals, Inc. (US) | 2015-01-20 | — | — | US | disclosed |
| WO-2010130424-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100120751-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2010-05-13 | — | — | US | disclosed |
| US-7335665-B2 | Spirocyclic piperidines as MCH1 antagonists and uses thereof | H - LUNDBECK A/S (DK) | 2008-02-26 | — | — | US | disclosed |
| US-7335665-B2 | Spirocyclic piperidines as MCH1 antagonists and uses thereof | H - LUNDBECK A/S (DK) | 2008-02-26 | — | — | US | disclosed |
| EP-1817036-A2 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20060270653-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-11-30 | — | — | US | disclosed |
| WO-2006058303-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-01 | — | — | WO | disclosed |
| US-4031224-A | 1,3-Dihydro-heteroarylspiro (isobenzofuran)s | AMERICAN HOECHST CORPORATION (US) | 1977-06-21 | — | — | US | disclosed |
| US-3985889-A | 1,3-DIHYDROSPIRO(ISOBENZOFURAN); ANALGETIC AGENTS | AMERICAN HOECHST CORPORATION (US) | 1976-10-12 | — | — | US | disclosed |
| US-3962259-A | TRANQUILIZERS, ANALGETIC AGENTS | AMERICAN HOECHST CORPORATION (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120751-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | AVPR1A, OXTR, AVPR1B | SIGMAR1 123/4885NPY5R 14/4885SSTR5 96/4885 |
| US-20160355522-A1 | SPIRO-OXAZOLONES | AVPR1A, AVPR1B, AVPR2 | SIGMAR1 178/4885NPY5R 162/4885SSTR5 195/4885 |
| US-10071095-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders | GRM2, GRM1, GRIA2 | SIGMAR1 334/4885NPY5R 317/4885SSTR5 1619/4885 |
| US-20060270653-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | SIGMAR1 237/4885NPY5R 356/4885SSTR5 509/4885 |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | GRM2, GRM1, GRIN2C | SIGMAR1 335/4885NPY5R 367/4885SSTR5 2110/4885 |
| US-20170008901-A1 | SPIRO-OXAZOLONES | AVPR1A, AVPR1B, AVPR2 | SIGMAR1 178/4885NPY5R 162/4885SSTR5 195/4885 |
| US-20160067245-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | GRM2, GRM1, GRIN2C | SIGMAR1 335/4885NPY5R 367/4885SSTR5 2110/4885 |
| US-20150141403-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | GRM2, GRM1, GRIN2C | SIGMAR1 332/4885NPY5R 385/4885SSTR5 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.